3rd generation glp 1 agonist Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports Schematic illustration of monoagonists, dual

10.2337/dc14-2364 [DOI] [PubMed] [Google Scholar] 85.Goldenberg RM

[DOI] [PubMed] [Google Scholar] 4.Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA

however, several drugs (including Novo Nordisks Wegovy and Eli Lillys Zepbound/Mounjaro) have recently been approved for chronic weight management

GLP-1s are available either as shots you take at home, or as a pill that is taken by mouth

[35] reported that a 6-month exenatide-based therapy produced a 42% relative reduction in intrahepatic lipid content, accompanied by a mean BW loss of 5 kg and significant decreases in both abdominal subcutaneous and visceral fat volumes

For example, administration of 2.4 mg/week of semaglutide (instead of 1 mg used in diabetics) for 68 weeks leads to average losses of 15% of initial body weight, approximately double that in type 2 diabetics (Figure 5A)